Elevance Health loses bid to challenge US Medicare star ratings

A federal judge in Texas dismissed Elevance Health's challenge against the U.S. Department of Health and Human Services (HHS) over its 2025 Medicare star ratings calculation. Elevance had argued that improper rounding of its score, which resulted in a 3.5-star rating instead of 4 stars for one contract, would cost the insurer at least $375 million in bonus payments. The court sided with HHS, ruling that Elevance failed to demonstrate major calculation flaws and that the rating process was too complex for judicial intervention, thereby upholding the Centers for Medicare & Medicaid Services' (CMS) established methodology for Medicare Advantage plan payments and potentially deterring similar future challenges from other insurers.

Analysis

A federal court's dismissal of Elevance Health's lawsuit solidifies a significant financial headwind for the insurer, confirming the loss of at least $375 million in potential bonus payments for its 2025 Medicare Advantage plans. The legal challenge centered on a contract that received a 3.749565 score, which was assigned a 3.5-star rating instead of the 4-star rating Elevance argued for based on rounding conventions. The judge's decision to side with the U.S. Department of Health and Human Services, citing a lack of major calculation flaws and the complexity of the rating process, establishes a critical precedent. This outcome, coupled with the recent dismissal of a similar lawsuit by Humana, underscores the judiciary's reluctance to intervene in the Centers for Medicare & Medicaid Services' (CMS) established rating methodology, reinforcing the regulatory power of CMS and diminishing the viability of legal recourse for insurers who narrowly miss higher star rating tiers.

Key Decisions for Investors

• Investors in Elevance Health should adjust 2025 financial models to reflect the confirmed loss of at least $375 million in high-margin bonus payments, as the potential for recovery through legal channels is now effectively eliminated.
• The ruling elevates regulatory risk across the Medicare Advantage sector, as it signals that judicial relief from unfavorable CMS star ratings is highly unlikely, making the annual ratings announcement a more definitive and impactful event for all participating insurers.
• Consider the strengthened competitive positioning of insurers with confirmed high star ratings for 2025, as this legal precedent solidifies their payment advantages and makes it more difficult for competitors like Elevance Health to challenge their lower-rated status.